What are the causes and management options for recurrent pleural effusion?

Recurrent Pleural Effusion: Causes and Management

Primary Causes

Malignancy is the most common cause of recurrent pleural effusion requiring intervention, followed by heart failure and other transudative causes. 1, 2

Malignant Causes

• Lung cancer, breast cancer, lymphoma, and ovarian cancer are the most frequent malignancies causing recurrent pleural effusions 1
• Small cell lung cancer, lymphoma, and breast cancer may respond to systemic chemotherapy, though effusions often still require local intervention during treatment 1

Non-Malignant Causes

• Congestive heart failure is the leading transudative cause, particularly in elderly patients with multiple comorbidities 3, 4
• Cirrhosis and nephrotic syndrome are other common transudative etiologies 1, 5
• Parapneumonic effusions and empyema can recur if inadequately drained initially 2

Drug-Induced Causes

• Dasatinib (tyrosine kinase inhibitor) causes pleural effusion in approximately 70% of patients, with median onset at 5-11 months but can occur up to 3 years into treatment 1
• Risk factors include age >60 years, cardiac disease, hypertension, and higher initial doses (140 mg vs 100 mg daily) 1

---

Management Algorithm

Step 1: Determine If Symptomatic

Observation alone is recommended for asymptomatic pleural effusions, regardless of size. 1, 2, 6

• Monitor closely as most patients eventually become symptomatic and require intervention 2, 6
• Do not perform therapeutic interventions in asymptomatic patients 2

Step 2: Initial Symptomatic Management

For all new symptomatic effusions, perform ultrasound-guided thoracentesis removing ≤1.5L to assess symptom relief and determine transudative vs exudative etiology. 1, 2, 6, 3

• Critical pitfall: Never remove >1.5L in a single session due to risk of re-expansion pulmonary edema 1, 2, 6
• Send pleural fluid for: cell count with differential, protein, LDH, glucose, pH, cytology, and cultures 2, 3, 7
• Obtain post-drainage chest radiograph to assess lung re-expansion 2

Step 3: Management Based on Etiology

A. Transudative Effusions (Heart Failure, Cirrhosis, Nephrosis)

Direct treatment toward the underlying medical condition first. 1, 2, 5

• Maximize cardiac therapy including diuretics and SGLT2 inhibitors before considering pleural interventions 3
• For refractory symptomatic effusions despite optimal medical therapy:
  • Repeated therapeutic thoracentesis (≤1.5L per session) is first-line for patients with very short life expectancy 1, 2, 6, 3
  • Indwelling pleural catheter (IPC) is preferred over pleurodesis for recurrent transudative effusions requiring frequent re-interventions 3, 8
  • Chemical pleurodesis can be considered for severe dyspnea with recurrent transudative effusion, though this is less commonly performed 5

B. Malignant Pleural Effusions

Either indwelling pleural catheter or chemical pleurodesis should be used as first-line definitive treatment for symptomatic malignant effusions with expandable lung, as both are equally effective. 2

Treatment Selection Algorithm:

For Expandable Lung (confirmed on post-drainage imaging):

• Talc pleurodesis achieves 93% success rate and is the most effective sclerosant 1, 6
  • Use small-bore tubes (10-14F) for drainage due to reduced discomfort and comparable efficacy 6
  • Administer intrapleural lignocaine (3 mg/kg; maximum 250 mg) prior to sclerosant 6
  • Do not delay pleurodesis once drainage and lung re-expansion are confirmed 6
• IPC reduces hospitalization (1 day vs 6 days for pleurodesis) and is preferred when minimizing hospital stay is priority 1, 6
  • Daily drainage increases spontaneous pleurodesis rates (46% achieved spontaneous pleurodesis in one study) 1, 6
  • Complication rate 14-30%, most commonly local cellulitis 1, 6

For Non-Expandable Lung, Failed Pleurodesis, or Trapped Lung:

• IPC is strongly preferred as pleurodesis will fail without complete lung expansion 2, 6
• Critical pitfall: Never attempt pleurodesis without confirming complete lung expansion 2

For Loculated Effusions:

• Consider intrapleural fibrinolytic therapy to decrease pleurodesis failure rate 6
• IPC remains an effective option 6

For Chemotherapy-Responsive Tumors (small cell lung cancer, lymphoma, breast cancer):

• Initiate systemic chemotherapy as primary treatment and do not delay systemic therapy for local treatment alone 2

Alternative Options for Failed First-Line Treatment:

• Thoracoscopy (VATS) for talc poudrage achieves 90% success rate with <0.5% perioperative mortality 1, 2
• Pleuroperitoneal shunts for trapped lung or failed pleurodesis, though require manual compression up to 400 times daily 1, 6
  • Shunt occlusion occurs in 12-25% requiring replacement 1
• Pleurectomy has 12% perioperative mortality and should be reserved only for highly selected patients with failed pleurodesis and excellent performance status 2

C. Parapneumonic Effusion/Empyema

Hospitalize all patients and initiate IV antibiotics covering common respiratory pathogens. 2

• Insert small-bore chest tube (≤14F) for drainage if pH <7.2 or glucose <3.3 mmol/L 2
• If loculated and cannot be completely evacuated, consider intrapleural thrombolytic therapy 5
• If thrombolytics fail, proceed to thoracoscopy or thoracotomy with decortication 5

D. Drug-Induced (Dasatinib)

Suspend treatment or reduce dose, with or without steroids and diuretics. 1

• For grade 3-4 effusions, thoracentesis may be necessary 1
• After first episode resolution, resume at same dose 1
• After second episode, reduce to next lower dose level (e.g., 100 mg to 80 mg daily) 1
• For further relapses, either stepwise lower to 50 mg/day or switch to alternative TKI 1

---

Critical Pitfalls to Avoid

• Never remove >1.5L during single thoracentesis due to risk of re-expansion pulmonary edema, which can occur even without extreme negative pleural pressure 1, 2, 6, 3
• Never attempt pleurodesis without confirming complete lung expansion on post-drainage imaging, as this will fail in trapped lung 2, 6
• Do not use intercostal tube drainage without pleurodesis as recurrence rate approaches 100% at 1 month 1
• Do not delay systemic chemotherapy in favor of local pleural treatment alone for chemotherapy-responsive malignancies 2

---

Special Management Considerations

IPC-Associated Infections

• Can usually be treated with antibiotics without catheter removal 2, 3
• Remove catheter only if infection fails to improve with antibiotics 2, 3

Partial Lung Re-expansion

• Chemical pleurodesis should still be attempted even with only partial pleural apposition, as it may provide symptomatic relief 6

Suction During Drainage

• Usually unnecessary, but if applied, use high-volume, low-pressure system with gradual increment to approximately -20 cm H₂O 6